SpyGlass Pharma Q2 net loss widens to $19.9 million; cash totals $234.2 million
SpyGlass Pharma reported its second quarter 2026 results, with a net loss of $19.9 million, or $0.59 per share, compared with $8.7 million, or $3.81 per share, a year earlier. Operating expenses rose as research and development and general and administrative costs increased, and the filing reports no revenue line. The company said its cash and short-term investments of $234.2 million are expected to fund planned operations through 2028.
Key points
- Net loss was $19.9 million in Q2 2026, up from $8.7 million in Q2 2025; per-share loss was $0.59 versus $3.81, on a larger weighted share count of 33,439,543 versus 2,277,521.
- Research and development expenses rose to $10.9 million from $7.3 million, mainly due to hiring clinical personnel.
- General and administrative expenses rose to $11.0 million from $2.0 million, mainly due to higher professional service fees and personnel costs.
- Cash, cash equivalents and short-term investments were $234.2 million on June 30, 2026, expected to fund operations through 2028.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.